ArticleResearch in pharmaceutical sciences2022

Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity.

Mohammad Hossein Ataee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.